Guildford, UK, 11 December 2007: ReNeuron Group plc (LSE: RENE.L) today announces that it will be participating in the London Biotechnology Network’s 7th Annual Genesis Conference, on 13-14 December 2007. Dr John Sinden, Chief Scientific Officer of ReNeuron, will give a development update on the Company’s ReN002 therapy for Type 1 diabetes, as part of the UK Biotechnology Company Showcase event on 14 December, at the BERR Conference Centre, London.

More information about the conference may be found at

Notes to editors

ReNeuron is a leading, UK-based stem cell therapy business. It is applying its novel stem cell platform technologies in the development of ground-breaking stem cell therapies to serve significant and unmet or poorly-met clinical needs. The Company operates from laboratories in Surrey, UK and Los Angeles, California, USA. ReNeuron has used its c-mycER technology to generate genetically stable neural stem cell lines. This technology platform has multi-national patent protection and is fully regulated by means of a chemically-induced safety switch. Cell growth can therefore be completely arrested prior to in vivo implantation.

ReNeuron has filed for approval to commence initial clinical studies in the US with its lead ReN001 stem cell therapy for chronic stroke disability. This represents the world’s first such filing concerning a neural stem cell treatment for a major neurological disorder. There are an estimated 50 million stroke survivors worldwide, approximately one half of which are left with permanent disabilities. The annual health and
social costs of caring for these patients is estimated to be in excess of £5 billion in the UK and in excess of US$50 billion in the US.

In addition to its stroke programme, ReNeuron is developing stem cell therapies for Parkinson’s disease, Huntington’s disease, Type 1 diabetes and diseases of the retina. The Company recently announced the acquisition of the business assets of AmCyte Inc. in the US, bringing clinically-tested cell encapsulation technology to ReNeuron’s ReN002 diabetes programme.

ReNeuron has leveraged its stem cell technologies into non-therapeutic areas � its ReNcell® range of cell lines for use in research and in drug discovery applications in the pharmaceutical industry. ReNeuron’s ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by Millipore Corporation. ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L.

Further information on ReNeuron and its products can be found at

Data sources: UK Stroke Association; American Stroke Association.

Further information

Michael Hunt, Chief Executive Officer
Dr John Sinden, Chief Scientific Officer
Tel: +44 (0)1483 302560

Financial Dynamics
David Yates
Lara Mott
Tel:+44 (0) 20 7831 3113

Robert Stanislaro
Tel :+1 212 850 5657